Schering Desloratadine Onset Of Action Is 1-2 Hours - EU Review Document
Executive Summary
Schering-Plough's clinical data for desloratadine supports a one-to-two hour onset of action claim for the antihistamine, the European Public Assessment Report states.
You may also be interested in...
Schering Clarinex Onset Of Action Studies Do Not Support Claim, FDA Finds
Schering's four Clarinex onset-of-action studies do not support a labeling claim, FDA concluded in its review of the NDA for the antihistamine
Schering Clarinex Onset Of Action Studies Do Not Support Claim, FDA Finds
Schering's four Clarinex onset-of-action studies do not support a labeling claim, FDA concluded in its review of the NDA for the antihistamine
Schering-Plough Clarinex Launch Strategy Follows Nexium Model
Schering-Plough's discounted pricing for the antihistamine Clarinex follows the model used by AstraZeneca to launch the anti-ulcer agent Nexium